n17350
onchilles pharma
['n17350']
onchilles pharma presents at aacr 2023 new preclinical data on n17350, a first-in-class immuno-oncology drug candidate with broad, potent, and direct tumor killing activity 
We provide a complete array of research services as required for Investigational New Drug Applications (IND).